These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32063140)

  • 1. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
    Pratt RM; West ML; Tennankore KK
    Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism.
    Zhang P; Yu Y; Gao Y; Yuan G; Zhang J; Wang W
    Hemodial Int; 2023 Apr; 27(2):E23-E28. PubMed ID: 36719850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
    Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
    Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
    Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
    J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab: a new agent in the management of hypercalcemia of malignancy.
    Thosani S; Hu MI
    Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab for immobilization-induced hypercalcemia in patients with end-stage renal disease.
    Thaker J; Geara AS
    Clin Nephrol; 2024 Oct; 102(4):254-256. PubMed ID: 38994596
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
    Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
    Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
    Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
    Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
    Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of high-dose denosumab in the management of immobilization-related hypercalcemia in an end-stage renal disease patient on hemodialysis: A case report and review of the literature.
    Zaitoun MF; Al-Alsheikh KA; Elnazer W
    Clin Nephrol; 2021 Dec; 96(6):353-356. PubMed ID: 34605398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
    Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
    Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
    Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
    Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report.
    Quiroga García V; Cirauqui Cirauqui B; Tobey Robaina L; López Sisamon D; Hardy-Werbin M; Blanca AB; Margelí Vila M
    Anticancer Drugs; 2016 Jun; 27(5):464-9. PubMed ID: 26813866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative.
    Kanagalingam T; Khan T; Sultan N; Cowan A; Thain J; Hoy C; Ledger S; Clemens KK
    Arch Osteoporos; 2023 Nov; 18(1):138. PubMed ID: 37985504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.
    Tzotzas T; Goropoulos A; Karras S; Terzaki A; Siolos A; Doumas A; Zaramboukas T; Tigas S
    Hormones (Athens); 2022 Mar; 21(1):171-176. PubMed ID: 34993886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study.
    Chen CL; Chen NC; Wu FZ; Wu MT
    Osteoporos Int; 2020 Aug; 31(8):1507-1516. PubMed ID: 32246167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
    Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
    Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
    Harsch IA; Konturek PC
    Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab.
    Kilci F; Demirsoy U; Jones JH; Çakır Ö; Çizmecioğlu-Jones FM
    J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1107-1112. PubMed ID: 35534911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.